Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research news
$15 million grant for integrative movement research
The National Science Foundation has granted $15 million to the Integrative Movement Sciences Institute at the University of California, Irvine, to support groundbreaking research led by Monica Daley, professor of ecology & evolutionary biology at the UCI School of Biological Sciences. The research aims to understand the intricate mechanics of muscle control during rapid, unsteady movements in complex environments.
MS drugs taken while breastfeeding may not affect child development
Taking certain medications for multiple sclerosis, called monoclonal antibodies, while breastfeeding may not affect the development of a child during the first three years of life, according to a preliminary study. The study examined four monoclonal antibodies for MS: natalizumab, ocrelizumab, rituximab and ofatumumab.
Research and customised care make aging with multiple sclerosis better
Physician scientists at The Ohio State University Wexner Medical Center and College of Medicine are studying why multiple sclerosis (MS) worsens as patients grow older. The researchers have identified new biomarkers that give insight into biological aging and its effects on MS disease progression and continue to discover new therapeutic targets through a grant from the National Institutes of Health.
Company news
NIH-funded Geriatrics Clinical Trials of BRAINBox TBI Concussion Test
BRAINBox Solutions has announced current and upcoming presentations of clinical trends and data at three leading, upcoming medical conferences from the HeadSMART II pivotal trial in adult patients and the National Institutes of Health (NIH) funded clinical trial in geriatric patients of its BRAINBox TBI concussion diagnostic and prognostic test.
OM1 to present research on Multiple Sclerosis at ACTRIMS Forum 2024
OM1, a real-world data, AI, and technology company with a focus on chronic diseases, has announced an upcoming poster presentation hosted by Dr. Carl Marci, OM1’s Chief Clinical Officer, Chief Psychiatrist and Managing Director of Mental Health and Neuroscience. The poster will focus on the use of an AI based estimation model used to help characterise disease progression in multiple sclerosis subtypes using real-world data.
Company advances to pivotal Alzheimer’s trial
Sinaptica Therapeutics, a clinical-stage company working on the development of a new class of personalised neuromodulation therapeutics to treat Alzheimer’s (AD) and other neurodegenerative diseases, has announced the appointment of Giovanni Frisoni, MD to complete the company’s Scientific Advisory Board (SAB). The SAB will help guide the company’s Phase 3 clinical development plans based on unprecedented Phase 2 data in Alzheimer’s showing >80% disease slowing on cognitive & functional endpoints.
Technology
Head-mounted fluorescence microscopes for neuroscience studies
PhysOrg reports that research groups led by Professor Bi Guoqiang, University of Science and Technology of China (USTC), and Professor Zhou Pengcheng from Shenzhen Institutes of Advanced Technology of Chinese Academy of Chinese proposed a design for ultra-compact head-mounted fluorescence microscopes, which were applied to neuro observations.
Major neurotech hub in Milan
The IRCCS San Raffaele Hospital and the Vita-Salute San Raffaele University announced the launch of a long-term partnership with the recently established Nicolelis Institute for Advanced Brain Studies of the Brazilian Alberto Santos Dumont Association for Research Support (AASDAP) aimed at creating a state-of-the-art Neurotech Hub on their campus in the city of Milan.
